Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.

R Dummer; GV Long; HA Tawbi; K Flaherty; PA Ascierto; PD Nathan; P Rutkowski; O Leonov; M Mandala; P Lorigan; PF Ferrucci; JJ Grob; N Meyer; H Gogas; D Stroyakovskiy; AM Arance; N Pakhle; S Waters; A Ribas; D Schadendorf

Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.

R Dummer, GV Long, HA Tawbi, K Flaherty, PA Ascierto, PD Nathan, P Rutkowski, O Leonov, M Mandala, P Lorigan, PF Ferrucci, JJ Grob, N Meyer, H Gogas, D Stroyakovskiy, AM Arance, N Pakhle, S Waters, A Ribas, D Schadendorf

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Dummer, R., Long, GV., Tawbi, HA., Flaherty, K., Ascierto, PA., Nathan, PD., Rutkowski, P., Leonov, O., Mandala, M., Lorigan, P., Ferrucci, PF., Grob, JJ., Meyer, N., Gogas, H., Stroyakovskiy, D., Arance, AM., Pakhle, N., Waters, S., Ribas, A., & Schadendorf, D. (2022). Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. Journal of Clinical Oncology, 40(16).

@article{7889519224d24b13aeebf3c5d250154e,

title = "Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.",

author = "R Dummer and GV Long and HA Tawbi and K Flaherty and PA Ascierto and PD Nathan and P Rutkowski and O Leonov and M Mandala and P Lorigan and PF Ferrucci and JJ Grob and N Meyer and H Gogas and D Stroyakovskiy and AM Arance and N Pakhle and S Waters and A Ribas and D Schadendorf",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

Dummer, R, Long, GV, Tawbi, HA, Flaherty, K, Ascierto, PA, Nathan, PD, Rutkowski, P, Leonov, O, Mandala, M, Lorigan, P, Ferrucci, PF, Grob, JJ, Meyer, N, Gogas, H, Stroyakovskiy, D, Arance, AM, Pakhle, N, Waters, S, Ribas, A & Schadendorf, D 2022, 'Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.', Journal of Clinical Oncology, vol. 40, no. 16.

Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. / Dummer, R; Long, GV; Tawbi, HA et al.
In: Journal of Clinical Oncology, Vol. 40, No. 16, 01.06.2022.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma

T2 - Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.

AU - Dummer, R

AU - Long, GV

AU - Tawbi, HA

AU - Flaherty, K

AU - Ascierto, PA

AU - Nathan, PD

AU - Rutkowski, P

AU - Leonov, O

AU - Mandala, M

AU - Lorigan, P

AU - Ferrucci, PF

AU - Grob, JJ

AU - Meyer, N

AU - Gogas, H

AU - Stroyakovskiy, D

AU - Arance, AM

AU - Pakhle, N

AU - Waters, S

AU - Ribas, A

AU - Schadendorf, D

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000863680302346&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Dummer R, Long GV, Tawbi HA, Flaherty K, Ascierto PA, Nathan PD et al. Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. Journal of Clinical Oncology. 2022 Jun 1;40(16).

Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.

UN SDGs

Other files and links

Cite this